Key Points
- COO Christopher Franklin Devall sold 45,000 shares on Dec. 8 at $3.85 for $173,250 and, combined with prior Dec. 5 and Dec. 3 sales (140,000 and 40,000 shares), has sold 225,000 shares for about $876,850, cutting his stake by 23.60% to 145,702 shares (≈$560,953).
- Dominari (NASDAQ:DOMH) has a market cap of roughly $71.7M, trades near $4.48 with a 1‑year range of $0.83–$13.58, and carries an average analyst rating of Hold, while institutional investors own about 42.48% of the stock.
Dominari Holdings Inc. (NASDAQ:DOMH - Get Free Report) COO Christopher Franklin Devall sold 45,000 shares of the company's stock in a transaction dated Monday, December 8th. The shares were sold at an average price of $3.85, for a total transaction of $173,250.00. Following the completion of the transaction, the chief operating officer directly owned 145,702 shares of the company's stock, valued at approximately $560,952.70. The trade was a 23.60% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Christopher Franklin Devall also recently made the following trade(s):
- On Friday, December 5th, Christopher Franklin Devall sold 140,000 shares of Dominari stock. The stock was sold at an average price of $3.82, for a total value of $534,800.00.
- On Wednesday, December 3rd, Christopher Franklin Devall sold 40,000 shares of Dominari stock. The stock was sold at an average price of $4.22, for a total value of $168,800.00.
Dominari Stock Performance
DOMH opened at $4.48 on Thursday. The company has a market capitalization of $71.72 million, a P/E ratio of 0.80 and a beta of 0.68. Dominari Holdings Inc. has a 1-year low of $0.83 and a 1-year high of $13.58. The company has a 50-day moving average of $5.22 and a 200-day moving average of $5.51.
Wall Street Analyst Weigh In
A number of brokerages recently weighed in on DOMH. Wall Street Zen downgraded shares of Dominari from a "buy" rating to a "hold" rating in a research report on Saturday, November 15th. Weiss Ratings reiterated a "hold (c-)" rating on shares of Dominari in a research report on Monday. One analyst has rated the stock with a Hold rating, According to data from MarketBeat, the company currently has an average rating of "Hold".
Get Our Latest Report on Dominari
Institutional Investors Weigh In On Dominari
Several large investors have recently made changes to their positions in the company. Magnus Financial Group LLC acquired a new position in shares of Dominari during the second quarter worth approximately $136,000. Jane Street Group LLC acquired a new position in Dominari during the 2nd quarter worth $158,000. Millennium Management LLC bought a new position in shares of Dominari in the third quarter worth $213,000. Geode Capital Management LLC raised its stake in shares of Dominari by 2.9% during the second quarter. Geode Capital Management LLC now owns 66,283 shares of the company's stock valued at $361,000 after purchasing an additional 1,866 shares in the last quarter. Finally, Two Sigma Investments LP acquired a new stake in Dominari in the third quarter worth about $771,000. Institutional investors and hedge funds own 42.48% of the company's stock.
Dominari Company Profile
(
Get Free Report)
Dominari Holdings Inc, a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
